Skip to main content
Premium Trial:

Request an Annual Quote

Epitome Biosystems, EMD Biosciences to Develop Tools Based on Epitome EpiTag Tech

NEW YORK, Sept. 16 (GenomeWeb News) - Epitome Biosystems and EMD Biosciences have signed a licensing and development agreement to develop products based on Epitome's EpiTag technology, the companies announced this week.


According to terms of the agreement, Epitome will develop reagents for the quantitative measurement of key interacellular signaling proteins. Products will be marketed and sold worldwide by EMD Biosciences under its Novagen and Calbiochem brands.


Epitome will receive a technology access fee, milestone-based development payments, and royalties on product sales.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.